Bill Text: TX HB488 | 2015-2016 | 84th Legislature | Introduced
Bill Title: Relating to the designation of certain synthetic compounds to Penalty Group 2 or 2-A of the Texas Controlled Substances Act.
Sponsorship: Partisan Bill (Republican 1)
Status: (Introduced - Dead) 2015-04-08 - Left pending in committee [HB488 Detail]
Download: Texas-2015-HB488-Introduced.html
| 84R1124 JSC-D | ||
| By: Guillen | H.B. No. 488 | |
|
|
||
|
|
||
| relating to the designation of certain synthetic compounds to | ||
| Penalty Group 2 or 2-A of the Texas Controlled Substances Act. | ||
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
| SECTION 1. Sections 481.002(5) and (6), Health and Safety | ||
| Code, are amended to read as follows: | ||
| (5) "Controlled substance" means a substance, | ||
| including a drug, an adulterant, and a dilutant, listed in | ||
| Schedules I through V or Penalty Group [ |
||
| 3, or [ |
||
| mixture, solution, or other substance containing a controlled | ||
| substance. | ||
| (6) "Controlled substance analogue" means: | ||
| (A) a substance with a chemical structure | ||
| substantially similar to the chemical structure of a controlled | ||
| substance in Schedule I or II or Penalty Group 1, 1-A, [ |
||
| 2-A; or | ||
| (B) a substance specifically designed to produce | ||
| an effect substantially similar to, or greater than, the effect of a | ||
| controlled substance in Schedule I or II or Penalty Group 1, 1-A, | ||
| [ |
||
| SECTION 2. Section 481.103(a), Health and Safety Code, is | ||
| amended to read as follows: | ||
| (a) Penalty Group 2 consists of: | ||
| (1) any quantity of the following hallucinogenic | ||
| substances, their salts, isomers, and salts of isomers, unless | ||
| specifically excepted, if the existence of these salts, isomers, | ||
| and salts of isomers is possible within the specific chemical | ||
| designation: | ||
| alpha-ethyltryptamine; | ||
| alpha-methyltryptamine; | ||
| 5-(2-aminopropyl)benzofuran (5-APB); | ||
| 6-(2-aminopropyl)benzofuran (6-APB); | ||
| 5-(2-aminopropyl)-2,3-dihydrobenzofuran | ||
| (5-APDB); | ||
| 6-(2-aminopropyl)-2,3-dihydrobenzofuran | ||
| (6-APDB); | ||
| 5-(2-aminopropyl)indole (Trade or other names: | ||
| 5-IT, 5-API); | ||
| 6-(2-aminopropyl)indole (Trade or other names: | ||
| 6-IT, 6-API); | ||
| Benzothiophenylcyclohexylpiperidine (BTCP); | ||
| 4-bromo-2, 5-dimethoxyamphetamine (some trade or | ||
| other names: 4-bromo-2, 5-dimethoxy-alpha-methylphenethylamine; | ||
| 4-bromo-2, 5-DMA); | ||
| 4-bromo-2, 5-dimethoxyphenethylamine; | ||
| 8-bromo-alpha-methyl-benzo[1,2-b:4,5-b']difuran- | ||
| 4-ethanamine (Trade or other name: Bromo-DragonFLY); | ||
| Bufotenine (some trade and other names: 3-(beta- | ||
| Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)- 5- | ||
| indolol; N, N-dimethylserotonin; 5-hydroxy-N, N- | ||
| dimethyltryptamine; mappine); | ||
| Desoxypipradrol (2-benzhydrylpiperidine); | ||
| Diethyltryptamine (some trade and other names: N, | ||
| N-Diethyltryptamine, DET); | ||
| 2, 5-dimethoxyamphetamine (some trade or other | ||
| names: 2, 5-dimethoxy-alpha-methylphenethylamine; 2, 5-DMA); | ||
| 2, 5-dimethoxy-4-ethylamphetamine (trade or other | ||
| name: DOET); | ||
| 2, 5-dimethoxy-4-(n)-propylthiophenethylamine | ||
| (trade or other name: 2C-T-7); | ||
| Dimethyltryptamine (trade or other name: DMT); | ||
| Diphenylprolinol (diphenyl(pyrrolidin-2-yl) | ||
| methanol, D2PM); | ||
| Dronabinol (synthetic) in sesame oil and | ||
| encapsulated in a soft gelatin capsule in a U.S. Food and Drug | ||
| Administration approved drug product (some trade or other names for | ||
| Dronabinol: (a6aR-trans)-6a,7,8,10a-tetrahydro- 6,6, 9- | ||
| trimethyl-3-pentyl-6H- dibenzo [b,d]pyran-1-ol or (-)-delta-9- | ||
| (trans)- tetrahydrocannabinol); | ||
| Ethylamine Analog of Phencyclidine (some trade or | ||
| other names: N-ethyl-1-phenylcyclohexylamine, (1- | ||
| phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, | ||
| cyclohexamine, PCE); | ||
| 2-ethylamino-2-(3-methoxyphenyl)cyclohexanone | ||
| (Trade or other name: methoxetamine); | ||
| Ibogaine (some trade or other names: 7-Ethyl-6, | ||
| 6, beta 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H- | ||
| pyrido [1', 2':1, 2] azepino [5, 4-b] indole; tabernanthe iboga.); | ||
| 5-iodo-2-aminoindane (5-IAI); | ||
| Mescaline; | ||
| 5-methoxy-N, N-diisopropyltryptamine | ||
| (5-MeO-DIPT); | ||
| 5-methoxy-N, N-diallyltryptamine (5MeO-DALT); | ||
| 5-methoxy-3, 4-methylenedioxy amphetamine; | ||
| 4-methoxyamphetamine (some trade or other names: | ||
| 4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine; | ||
| PMA); | ||
| 4-methoxymethamphetamine (PMMA); | ||
| 2-(2-methoxyphenyl)-2-(methylamino)cyclohexanone | ||
| (Trade or other names: 2-MeO-ketamine; methoxyketamine); | ||
| 1-methyl- 4-phenyl-4-propionoxypiperidine (MPPP, | ||
| PPMP); | ||
| 4-methyl-2, 5-dimethoxyamphetamine (some trade | ||
| and other names: 4-methyl-2, 5-dimethoxy-alpha- | ||
| methylphenethylamine; "DOM"; "STP"); | ||
| 3,4-methylenedioxy methamphetamine (MDMA, MDM); | ||
| 3,4-methylenedioxy amphetamine; | ||
| 3,4-methylenedioxy N-ethylamphetamine (Also | ||
| known as N-ethyl MDA); | ||
| 5,6-methylenedioxy-2-aminoindane (MDAI); | ||
| Nabilone (Another name for nabilone: (+)-trans- | ||
| 3-(1,1-dimethylheptyl)- 6,6a, 7,8,10,10a-hexahydro-1-hydroxy- 6, | ||
| 6-dimethyl-9H-dibenzo[b,d] pyran-9-one; | ||
| N-benzylpiperazine (some trade or other names: | ||
| BZP; 1-benzylpiperazine); | ||
| N-ethyl-3-piperidyl benzilate; | ||
| N-hydroxy-3,4-methylenedioxyamphetamine (Also | ||
| known as N-hydroxy MDA); | ||
| 4-methylaminorex; | ||
| N-methyl-3-piperidyl benzilate; | ||
| O-Acetylpsilocin (Trade or other name: | ||
| 4-Aco-DMT); | ||
| Parahexyl (some trade or other names: 3-Hexyl-1- | ||
| hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b, d] | ||
| pyran; Synhexyl); | ||
| 1-Phenylcyclohexylamine; | ||
| 1-Piperidinocyclohexanecarbonitrile (PCC); | ||
| Psilocin; | ||
| Psilocybin; | ||
| Pyrrolidine Analog of Phencyclidine (some trade | ||
| or other names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP); | ||
| Tetrahydrocannabinols, other than marihuana, and | ||
| synthetic equivalents of the substances contained in the plant, or | ||
| in the resinous extractives of Cannabis, or synthetic substances, | ||
| derivatives, and their isomers with similar chemical structure and | ||
| pharmacological activity such as: | ||
| delta-1 cis or trans tetrahydrocannabinol, | ||
| and their optical isomers; | ||
| delta-6 cis or trans tetrahydrocannabinol, | ||
| and their optical isomers; | ||
| delta-3, 4 cis or trans | ||
| tetrahydrocannabinol, and its optical isomers; | ||
| compounds of these structures, regardless of | ||
| numerical designation of atomic positions, since nomenclature of | ||
| these substances is not internationally standardized; | ||
| Thiophene Analog of Phencyclidine (some trade or | ||
| other names: 1-[1-(2-thienyl) cyclohexyl] piperidine; 2-Thienyl | ||
| Analog of Phencyclidine; TPCP, TCP); | ||
| 1-pyrrolidine (some trade or other name: TCPy); | ||
| 1-(3-trifluoromethylphenyl)piperazine (trade or | ||
| other name: TFMPP); and | ||
| 3,4,5-trimethoxy amphetamine; | ||
| (2) Phenylacetone (some trade or other names: | ||
| Phenyl-2-propanone; P2P, Benzymethyl ketone, methyl benzyl | ||
| ketone); | ||
| (3) unless specifically excepted or unless listed in | ||
| another Penalty Group, a material, compound, mixture, or | ||
| preparation that contains any quantity of the following substances | ||
| having a potential for abuse associated with a depressant or | ||
| stimulant effect on the central nervous system: | ||
| Aminorex (some trade or other names: aminoxaphen; | ||
| 2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5- | ||
| phenyl-2-oxazolamine); | ||
| Amphetamine, its salts, optical isomers, and | ||
| salts of optical isomers; | ||
| Cathinone (some trade or other names: 2-amino-1- | ||
| phenyl-1-propanone, alpha-aminopropiophenone, 2- | ||
| aminopropiophenone); | ||
| Etaqualone and its salts; | ||
| Etorphine Hydrochloride; | ||
| Fenethylline and its salts; | ||
| Lisdexamfetamine, including its salts, isomers, | ||
| and salts of isomers; | ||
| Mecloqualone and its salts; | ||
| Methaqualone and its salts; | ||
| Methcathinone (some trade or other names: 2- | ||
| methylamino-propiophenone; alpha-(methylamino)propriophenone; | ||
| 2-(methylamino)-1-phenylpropan-1-one; alpha-N- | ||
| methylaminopropriophenone; monomethylpropion; ephedrone, N- | ||
| methylcathinone; methylcathinone; AL-464; AL-422; AL-463; and UR | ||
| 1431); | ||
| N-Ethylamphetamine, its salts, optical isomers, | ||
| and salts of optical isomers; and | ||
| N,N-dimethylamphetamine (some trade or other | ||
| names: N,N,alpha-trimethylbenzeneethaneamine; | ||
| N,N,alpha-trimethylphenethylamine), its salts, optical isomers, | ||
| and salts of optical isomers; and | ||
| (4) any compound structurally derived from | ||
| 2-aminopropanal by substitution at the 1-position with any | ||
| monocyclic or fused-polycyclic ring system, including: | ||
| (A) compounds further modified by: | ||
| (i) substitution in the ring system to any | ||
| extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, | ||
| hydroxyl, or halide substituents), whether or not further | ||
| substituted in the ring system by other substituents; | ||
| (ii) substitution at the 3-position with an | ||
| acyclic alkyl substituent; or | ||
| (iii) substitution at the 2-amino nitrogen | ||
| atom with alkyl, [ |
||
| inclusion of the 2-amino nitrogen atom in a cyclic structure; and | ||
| (B) by example, compounds such as: | ||
| 4-Methoxymethcathinone (Also known as | ||
| Methedrone); | ||
| 4-Methylmethcathinone (Also known as | ||
| Mephedrone); | ||
| 3,4-Dimethylmethcathinone (Also known as | ||
| 3,4-DMMC); | ||
| 3-Fluoromethcathinone (Also known as 3-FMC); | ||
| 4-Fluoromethcathinone (Also known as | ||
| Flephedrone); | ||
| 3,4-Methylenedioxy-N-methylcathinone (Also | ||
| known as Methylone); | ||
| 3,4-Methylenedioxypyrovalerone (Also known | ||
| as MDPV); | ||
| alpha-Pyrrolidinopentiophenone (Also known | ||
| as alpha-PVP); | ||
| Naphthylpyrovalerone (Also known as | ||
| Naphyrone); | ||
| beta-Keto-N-methylbenzodioxolylpropylamine | ||
| (Also known as Butylone); | ||
| beta-Keto-N-methylbenzodioxolylpentanamine | ||
| (Also known as Pentylone); | ||
| beta-Keto-Ethylbenzodioxolylbutanamine | ||
| (Also known as Eutylone); and | ||
| 3,4-methylenedioxy-N-ethylcathinone (Also | ||
| known as Ethylone). | ||
| SECTION 3. Section 481.1031, Health and Safety Code, is | ||
| amended to read as follows: | ||
| Sec. 481.1031. PENALTY GROUP 2-A. Penalty Group 2-A | ||
| consists of any quantity of a synthetic chemical compound that is a | ||
| cannabinoid receptor agonist and mimics the pharmacological effect | ||
| of naturally occurring cannabinoids, including: | ||
| naphthoylindoles structurally derived from | ||
| 3-(1-naphthoyl)indole with or without [ |
||
| nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, | ||
| cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl) | ||
| methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, | ||
| (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl, | ||
| or 2-(4-morpholinyl)ethyl, whether or not further substituted in | ||
| the indole ring to any extent, whether or not substituted in the | ||
| napthyl ring to any extent, including: | ||
| AM-2201; | ||
| JWH-004; | ||
| JWH-007; | ||
| JWH-009; | ||
| JWH-015; | ||
| JWH-016; | ||
| JWH-018; | ||
| JWH-019; | ||
| JWH-020; | ||
| JWH-046; | ||
| JWH-047; | ||
| JWH-048; | ||
| JWH-049; | ||
| JWH-050; | ||
| JWH-073; | ||
| JWH-076; | ||
| JWH-079; | ||
| JWH-080; | ||
| JWH-081; | ||
| JWH-082; | ||
| JWH-083; | ||
| JWH-093; | ||
| JWH-094; | ||
| JWH-095; | ||
| JWH-096; | ||
| JWH-097; | ||
| JWH-098; | ||
| JWH-099; | ||
| JWH-100; | ||
| JWH-116; | ||
| JWH-122; | ||
| JWH-148; | ||
| JWH-149; | ||
| JWH-153; | ||
| JWH-159; | ||
| JWH-164; | ||
| JWH-165; | ||
| JWH-166; | ||
| JWH-180; | ||
| JWH-181; | ||
| JWH-182; | ||
| JWH-189; | ||
| JWH-193; | ||
| JWH-198; | ||
| JWH-200; | ||
| JWH-210; | ||
| JWH-211; | ||
| JWH-212; | ||
| JWH-213; | ||
| JWH-234; | ||
| JWH-235; | ||
| JWH-239; | ||
| JWH-240; | ||
| JWH-241; | ||
| JWH-242; | ||
| JWH-258; | ||
| JWH-259; | ||
| JWH-260; | ||
| JWH-262; | ||
| JWH-267; | ||
| JWH-386; | ||
| JWH-387; | ||
| JWH-394; | ||
| JWH-395; | ||
| JWH-397; | ||
| JWH-398; | ||
| JWH-399; | ||
| JWH-400; | ||
| JWH-412; | ||
| JWH-413; and | ||
| JWH-414; | ||
| naphthylmethylindones structurally derived from | ||
| 1H-indol-3-yl-(1-naphthyl)methane with or without [ |
||
| substitution at the nitrogen atom of the indole ring by alkyl, | ||
| haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | ||
| (N-methylpiperidin-2-yl)methyl, cyanoalkyl, (N-methylpyrrolidin- | ||
| 2-yl)methyl, (tetrahydropyran-4-yl)methyl, ((N-methyl)-3- | ||
| morpholinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not | ||
| further substituted in the indole ring to any extent, whether or not | ||
| substituted in the naphthyl ring to any extent, including: | ||
| JWH-175; | ||
| JWH-184; | ||
| JWH-185; | ||
| JWH-192; | ||
| JWH-194; | ||
| JWH-195; | ||
| JWH-196; | ||
| JWH-197; and | ||
| JWH-199; | ||
| naphthoylpyrroles structurally derived from | ||
| 3-(1-naphthoyl)pyrrole with or without [ |
||
| nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | ||
| cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl) | ||
| methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, | ||
| (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl, | ||
| or 2-(4-morpholinyl)ethyl, whether or not further substituted in | ||
| the pyrrole ring to any extent, whether or not substituted in the | ||
| naphthyl ring to any extent, including: | ||
| JWH-030; | ||
| JWH-145; | ||
| JWH-146; | ||
| JWH-147; | ||
| JWH-150; | ||
| JWH-156; | ||
| JWH-243; | ||
| JWH-244; | ||
| JWH-245; | ||
| JWH-246; | ||
| JWH-292; | ||
| JWH-293; | ||
| JWH-307; | ||
| JWH-308; | ||
| JWH-309; | ||
| JWH-346; | ||
| JWH-347; | ||
| JWH-348; | ||
| JWH-363; | ||
| JWH-364; | ||
| JWH-365; | ||
| JWH-366; | ||
| JWH-367; | ||
| JWH-368; | ||
| JWH-369; | ||
| JWH-370; | ||
| JWH-371; | ||
| JWH-372; | ||
| JWH-373; and | ||
| JWH-392; | ||
| naphthylmethylindenes structurally derived from | ||
| 1-(1-naphthylmethyl)indene with or without [ |
||
| the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, | ||
| cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl) | ||
| methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, | ||
| (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl, | ||
| or 2-(4-morpholinyl)ethyl, whether or not further substituted in | ||
| the indene ring to any extent, whether or not substituted in the | ||
| naphthyl ring to any extent, including: | ||
| JWH-171; | ||
| JWH-172; | ||
| JWH-173; and | ||
| JWH-176; | ||
| phenylacetylindoles structurally derived from | ||
| 3-phenylacetylindole with or without [ |
||
| nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, | ||
| cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl) | ||
| methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, | ||
| (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl, | ||
| or 2-(4-morpholinyl)ethyl, whether or not further substituted in | ||
| the indole ring to any extent, whether or not substituted in the | ||
| phenyl ring to any extent, including: | ||
| AM-694; | ||
| AM-1241; | ||
| JWH-167; | ||
| JWH-203; | ||
| JWH-204; | ||
| JWH-205; | ||
| JWH-206; | ||
| JWH-208; | ||
| JWH-237; | ||
| JWH-248; | ||
| JWH-249; | ||
| JWH-250; | ||
| JWH-251; | ||
| JWH-252; | ||
| JWH-253; | ||
| JWH-302; | ||
| JWH-303; | ||
| JWH-305; | ||
| JWH-306; | ||
| JWH-311; | ||
| JWH-312; | ||
| JWH-313; | ||
| JWH-314; and | ||
| JWH-315; | ||
| cyclohexylphenols structurally derived from | ||
| 2-(3-hydroxycyclohexyl)phenol with or without [ |
||
| the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, | ||
| cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl) | ||
| methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, | ||
| (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl, | ||
| or 2-(4-morpholinyl)ethyl, whether or not substituted in the | ||
| cyclohexyl ring to any extent, including: | ||
| CP-55,940; | ||
| CP-47,497; | ||
| analogues of CP-47,497, including VII, V, VIII, I, | ||
| II, III, IV, IX, X, XI, XII, XIII, XV, and XVI; | ||
| JWH-337; | ||
| JWH-344; | ||
| JWH-345; and | ||
| JWH-405; [ |
||
| benzoylindoles structurally derived from | ||
| 3-(1-naphthoyl)indole with or without substitution at the nitrogen | ||
| atom of the indole ring with alkyl, haloalkyl, alkenyl, | ||
| cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl) | ||
| methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, | ||
| (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl, | ||
| or 2-(4-morpholinyl)ethyl, whether or not further substituted in | ||
| the indole ring to any extent, whether or not substituted in the | ||
| phenyl ring to any extent, including: | ||
| 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4); and | ||
| 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4- | ||
| methoxybenzoyl)indole (Pravadoline or WIN 48,098); and | ||
| cannabinol derivatives, except where contained in | ||
| marihuana, including tetrahydro derivatives of cannabinol and | ||
| 3-alkyl homologues of cannabinol or of its tetrahydro derivatives, | ||
| such as: | ||
| Nabilone; | ||
| HU-210; | ||
| HU-211; and | ||
| WIN-55,212-2. | ||
| SECTION 4. Section 481.106, Health and Safety Code, is | ||
| amended to read as follows: | ||
| Sec. 481.106. CLASSIFICATION OF CONTROLLED SUBSTANCE | ||
| ANALOGUE. For the purposes of the prosecution of an offense under | ||
| this subchapter involving the manufacture, delivery, or possession | ||
| of a controlled substance, Penalty Groups 1, 1-A, [ |
||
| include a controlled substance analogue that: | ||
| (1) has a chemical structure substantially similar to | ||
| the chemical structure of a controlled substance listed in the | ||
| applicable penalty group; or | ||
| (2) is specifically designed to produce an effect | ||
| substantially similar to, or greater than, a controlled substance | ||
| listed in the applicable penalty group. | ||
| SECTION 5. The change in law made by this Act applies only | ||
| to an offense committed on or after the effective date of this Act. | ||
| An offense committed before the effective date of this Act is | ||
| governed by the law in effect on the date the offense was committed, | ||
| and the former law is continued in effect for that purpose. For | ||
| purposes of this section, an offense was committed before the | ||
| effective date of this Act if any element of the offense occurred | ||
| before that date. | ||
| SECTION 6. This Act takes effect September 1, 2015. | ||
